Vaccine potential of antigen cocktails composed of recombinant Toxoplasma gondii TgPI-1, ROP2 and GRA4 proteins against chronic toxoplasmosis in C3H mice

Picchio, Mariano S.; Sánchez, Vanesa Roxana; Arcon, Nadia; Soto, Ariadna Soledad; Sibilia, Matias Perrone; Aldirico, María de los ängeles; Urrutia, Mariela; Moretta, Rosalía; Fenoy, Ignacio Martín; Goldman, Alejandra; Martin, Valentina

doi:10.1016/j.exppara.2018.01.006

Cited by 14 publications

(9 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…P + R + G vaccine formulations induced significant decreases in the number of cysts per brain compared to the control group. According to the levels of IgG1 and IgG2a subclasses P + R + G vaccine groups showed a mixed Th1/Th2 immunity [44].…”

Section: Discussionmentioning

confidence: 97%

“…In literature, multivalent recombinant protein vaccines have been developed against toxoplasmosis. In these studies, surface related antigens rSAG1, rSAG2, rSAG3, rSRS1, rP54, rSRS4, and rSRS9; dense granule proteins rGRA1, rGRA2, rGRA4, rGRA5, rGRA6, and rGRA7; rhoptry proteins rROP2, rROP4, and rROP5 as well as rTgPI-1, rMAG1 and rBAG1 have been used [24,[34][35][36][37][38][39][40][41][42][43][44].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Development of a hexavalent recombinant protein vaccine adjuvanted with Montanide ISA 50 V and determination of its protective efficacy against acute toxoplasmosis

et al. 2020

View full text Add to dashboard Cite

Background: Toxoplasma gondii is an obligate intracellular parasite that can infect almost all warm-blooded animals, avian species and humans. Toxoplasmosis is asymptomatic in healthy individuals, whereas it may lead to death in immune suppressed or deficient patients. A vaccine against T. gondii is required to prevent consequences of the infection. The aim of this study is to generate a multivalent recombinant protein vaccine against T. gondii. Methods: 49 previously discovered antigenic proteins of T gondii were evaluated by their expression level in E. coli and by comprehensive bioinformatics analyses to determine antigenic epitopes. Based on these analyses, six vaccine candidate proteins were selected to generate a hexavalent recombinant protein vaccine adjuvanted with Montanide ISA 50 V. Humoral and cellular immune responses were determined by flow cytometry and ELISA. Vaccinated mice were challenged with T. gondii Ankara strain tachyzoites.Results: In mice vaccinated with hexavalent vaccine, strong total IgG (P < 0.0001) and IgG2a (P < 0.001) responses were induced compared to controls, the ratio of CD4 + and CD8 + T lymphocytes secreting IFN-γ increased, and significantly higher extracellular IFN-γ secretion was achieved compared to the controls (P < 0.001). The survival time of the vaccinated mice increased to 8.38 ± 2.13 days which was significantly higher than controls (P < 0.01). Conclusions: Altogether, these results show that the hexavalent vaccine which is developed for the first time against T. gondii induced strong and balanced Th1 and Th2 immune responses as well as conferred significant protection against challenge with lethal toxoplasmosis in murine model.

show abstract

Section: Discussionmentioning

confidence: 97%

Section: Discussionmentioning

confidence: 99%

Development of a hexavalent recombinant protein vaccine adjuvanted with Montanide ISA 50 V and determination of its protective efficacy against acute toxoplasmosis

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Previous studies have shown that a multicomponent vaccine may offer better protection than a single antigen ( 16 – 19 ) due to the elevated numbers of T. gondii -specific CTLs, and the subsequent increase in the production of antigen-specific cytokine gamma-interferon (IFN-γ) ( 19 , 20 ). A combination of different antigens, in theory, contain more CTL epitopes and are considered superior to a single antigen for protecting the host against T. gondii infection ( 14 , 21 ).…”

Section: Introductionmentioning

confidence: 99%

Immunization With a DNA Vaccine Cocktail Encoding TgPF, TgROP16, TgROP18, TgMIC6, and TgCDPK3 Genes Protects Mice Against Chronic Toxoplasmosis

et al. 2018

View full text Add to dashboard Cite

Toxoplasmosis is a zoonotic disease caused by the intracellular protozoan Toxoplasma gondii; and a major source of infection in humans is via ingestion of T. gondii tissue cysts. Ultimately, the goal of anti-toxoplasmosis vaccines is to elicit a sustainable immune response, capable of preventing formation of the parasite tissue cysts—or, at least, to restrain its growth. In this study, we formulated a cocktail DNA vaccine and investigated its immunologic efficacy as a protection against the establishment of T. gondii cysts in the mouse brain. This multicomponent DNA vaccine, encoded the TgPF, TgROP16, TgROP18, TgMIC6, and TgCDPK3 genes, which play key roles in the pathogenesis of T. gondii infection. Results showed that mice immunized via intramuscular injection three times, at 2-week intervals with this multicomponent DNA vaccine, mounted a strong humoral and cellular immune response, indicated by significantly high levels of total IgG, CD4+ and CD8+ T lymphocytes, and antigen-specific lymphocyte proliferation when compared with non-immunized mice. Immunization also induced a mixed Th1/Th2 response, with a slightly elevated IgG2a to IgG1 ratio. The increased production of proinflammatory cytokines gamma-interferon, interleukin-2, and interleukin-12 (p < 0.0001) correlated with increased expression of p65/RelA and T-bet genes of the NF-κB pathway. However, no significant difference was detected in level of interleukin-4 (p > 0.05). The number of brain cysts in immunized mice was significantly less than those in non-immunized mice (643.33 ± 89.63 versus 3,244.33 ± 96.42, p < 0.0001), resulting in an 80.22% reduction in the parasite cyst burden. These findings indicate that a multicomponent DNA vaccine, encoding TgPF, TgROP16, TgROP18, TgMIC6, and TgCDPK3 genes, shows promise as an immunization strategy against chronic toxoplasmosis in mice, and calls for a further evaluation in food-producing animals.

show abstract

“…Economically, the vaccine could also reduce losses in the livestock industry [26]. Thus, achieving effective vaccines against toxoplasmosis is a high priority and extremely important, given the high incidence of the disease worldwide, as well as the serious veterinary and clinical outcomes of the parasite, including chorioretinitis, abortions, mental defects, and death [26,27].…”

Section: Approaches In Development Of Vaccines Against Toxoplasmosismentioning

confidence: 99%

Epitope-based vaccine as a universal vaccination strategy against Toxoplasma gondii infection: A mini-review

et al. 2019

View full text Add to dashboard Cite

Despite the significant progress in the recent efforts toward developing an effective vaccine against toxoplasmosis, the search for new protective vaccination strategy still remains a challenge and elusive goal because it becomes the appropriate way to prevent the disease. Various experimental approaches in the past few years showed that developing a potential vaccine against the disease can be achievable. The combination of multi-epitopes expressing different stages of the parasite life cycle has become an optimal strategy for acquiring a potent, safe, and effective vaccine. Epitope-based vaccines have gained attention as alternative vaccine candidates due to their ability of inducing protective immune responses. This mini-review highlights the current status and the prospects of Toxoplasma gondii vaccine development along with the application of epitope-based vaccine in the future parasite immunization as a novel under development and evaluation strategy.

show abstract

Vaccine potential of antigen cocktails composed of recombinant Toxoplasma gondii TgPI-1, ROP2 and GRA4 proteins against chronic toxoplasmosis in C3H mice

Cited by 14 publications

References 23 publications

Development of a hexavalent recombinant protein vaccine adjuvanted with Montanide ISA 50 V and determination of its protective efficacy against acute toxoplasmosis

Development of a hexavalent recombinant protein vaccine adjuvanted with Montanide ISA 50 V and determination of its protective efficacy against acute toxoplasmosis

Immunization With a DNA Vaccine Cocktail Encoding TgPF, TgROP16, TgROP18, TgMIC6, and TgCDPK3 Genes Protects Mice Against Chronic Toxoplasmosis

Epitope-based vaccine as a universal vaccination strategy against Toxoplasma gondii infection: A mini-review

Contact Info

Product

Resources

About